跳转至内容
Merck
CN

D8517

Sigma-Aldrich

右旋糖酐铁

95-105 mg/mL (Iron content), solution

别名:

葡聚糖铁

登录查看公司和协议定价

选择尺寸


关于此项目

化学文摘社编号:
MDL编号:
UNSPSC代码:
12352201
NACRES:
NA.25
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

synthetic

质量水平

无菌性

aseptically filled

方案

95-105 mg/mL (Iron content)

表单

solution

包含

0.5% phenol as preservative

组成

Iron, ~100 mg/mL

颜色

brown

有效pH范围

4 - 6.5

储存温度

room temp

SMILES字符串

[Fe].[S](=O)(=O)(O)O

InChI

1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)

InChI key

MVZXTUSAYBWAAM-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

应用

铁-葡聚糖(氢氧化铁葡聚糖复合物)可用作静脉内铁转运制剂。铁-葡聚糖可用于诱导铁超负荷以研究其作用和预防措施。

其他说明

为了全面了解我们针对客户研究提供的各种葡聚糖产品,建议您访问我们的碳水化合物分类页面。

象形图

Health hazardExclamation mark

警示用语:

Danger

危险声明

危险分类

Carc. 1B - Skin Sens. 1

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

D L Burns et al.
Nutrition (Burbank, Los Angeles County, Calif.), 11(2), 163-168 (1995-03-01)
Iron dextran was introduced more than 30 yr ago for the parenteral treatment of iron deficiency anemia that is refractory to oral therapy. Iron dextran is a preparation of ferric hydroxide complexed with a low molecular weight fraction of dextran.
Markus R Jahn et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 78(3), 480-491 (2011-03-29)
The treatment of iron deficiency anemia with polynuclear iron formulations is an established therapy in patients with chronic kidney disease but also in other disease areas like gastroenterology, cardiology, oncology, pre/post operatively and obstetrics' and gynecology. Parenteral iron formulations represent
Zachariah DeFilipp et al.
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 9(1), 129-132 (2012-08-08)
Iron deficiency is a major postoperative complication of Roux-en-Y gastric bypass surgery. Oral replacement can fail to correct the deficiency. Thus, recourse to parenteral iron administration might be necessary. Our objective was to evaluate the effectiveness and safety of a
C Egger et al.
Ultraschall in der Medizin (Stuttgart, Germany : 1980), 33(6), 587-592 (2012-11-17)
To check the feasibility of the easy quantification of tumor vascularization derived from dynamic contrast-enhanced ultrasound (DCE-US) in comparison to dynamic contrast-enhanced computed tomography (DCE-CT) in patients with hepatocellular carcinoma (HCC). 19 patients with cirrhosis and histologically proven HCC prospectively
Maureen M Okam et al.
American journal of hematology, 87(11), E123-E124 (2012-09-12)
Oral iron replacement is the standard therapy in iron-deficiency anemia (IDA). However, 59% of patients have gastrointestinal toxicity. With impaired iron uptake from the gastrointestinal tract (in anemia of chronic disease (ACD) or after bariatric surgery), suboptimal responsiveness to exogenous

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持